SecBot SecBot
6-K ·Filed Nov 10, 2026

IMTX

Immatics N.V.
NEUTRAL
Impact 5/10
Horizonmonths Processed6d 19h ago SEC0001193125-26-454401
6-K: Earnings release
Actionable Insight • Neutral

The key catalyst is SUPRAME Phase 3 topline data in H1 2027. Monitor enrollment completion by year-end 2026 and any updates on the BLA submission timeline. The activist stake by Perceptive Advisors adds a governance overlay, but the stock's trajectory depends on clinical execution.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

IMTX drug pipeline →

IMA203

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3
Time to market
If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
Next catalyst
None dated

What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.

Price Chart

Loading chart...

Executive Summary

Immatics reported Q3 2026 collaboration revenue of EUR 6.9M (up 33% YoY) and a net loss of EUR 76.0M (up 50% YoY), driven by increased R&D spending on the SUPRAME Phase 3 trial. The company guided that SUPRAME enrollment remains on track to complete by year-end, with topline data expected in H1 2027 and a BLA submission in 2027. Cash and financial assets of EUR 472.3M extend the cash runway into Q4 2028.

Key Financial Metrics

EPS
−$0.50
Revenue
$6.9M
+33.5% YoY

Key Facts

  • Q3 2026 collaboration revenue EUR 6.9M vs EUR 5.2M in Q3 2025 (+33% YoY)
  • Q3 2026 net loss EUR 76.0M vs EUR 50.5M in Q3 2025 (+50% YoY)
  • R&D expenses EUR 70.3M in Q3 2026 vs EUR 47.2M in Q3 2025 (+49% YoY), driven by SUPRAME Phase 3 trial costs
  • Cash and financial assets EUR 472.3M as of September 30, 2026; cash runway extended into Q4 2028
  • SUPRAME Phase 3 enrollment on track to complete required randomizations by year-end 2026
  • Topline data from SUPRAME final PFS analysis expected H1 2027, BLA submission in 2027
  • Perceptive Advisors holds an activist stake via SC 13D/A filed August 27, 2026

Financial Impact

Q3 2026 revenue EUR 6.9M (up EUR 1.7M YoY); net loss EUR 76.0M (up EUR 25.5M YoY); cash burn EUR 163.2M in 9M 2026 vs EUR 118.0M in 9M 2025

revenuenet losscash burnR&D expenses

Risk Factors

  • SUPRAME trial could miss the primary PFS endpoint, delaying or preventing BLA submission
  • Cash burn is accelerating (EUR 163.2M in 9M 2026 vs EUR 118.0M in 9M 2025), requiring future capital raises
  • BMS collaboration ended in August 2026, reducing future collaboration revenue visibility
  • Pre-funded warrants (4.3M shares) represent potential dilution if exercised

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-454401
Document: imtx-ex99_2.htm0001193125-26-454401
Document: immatics_n.v._6-k_q3_26.htm0001193125-26-454401
Document: 0001193125-26-454401-index-headers.html0001193125-26-454401
Document: 0001193125-26-454401-index.html0001193125-26-454401
Document: 0001193125-26-454401.txt0001193125-26-454401
Earnings Context (Synthetic; results releases only)0001193125-26-454401

Track record

23 reports on IMTX

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 Viewing No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026